Resurgence of Ibogaine as a Psychedelic Addiction Treatment | Wonderland 2023
Ibogaine is a non-classical psychedelic that breaks the cycle of addiction to opioids, cocaine and other abused drugs. In the 1960’s, American and European self-help groups provided public testimonials that a single dose of ibogaine alleviated drug craving, opioid withdrawal symptoms, and prevented relapse for weeks, months and sometimes years. The claimed therapeutic benefits of ibogaine which treat the underlying disease instead of targeting symptoms to prevent relapse support the current resurgence of ibogaine’s clinical development for inpatient use.
Featured Speakers
Deborah Mash, CEO & Founder, DemeRx
Deborah Mash is one of the world's foremost experts on the hallucinogenic drug ibogaine. She is the CEO and Founder of DemeRx Inc., a clinical stage drug development company advancing ibogaine and noribogaine for the treatment of opioid use disorder. DemeRx has partnered with ATAI Life Sciences -- a global biotech platform with a special focus on psychedelic medicine -- to develop ibogaine for those suffering from opioid use disorder.
Wonderland is the place to discover the fascinating worlds of psychedelic medicine, mental health, and longevity. An immersive environment, our conference programming and experience floor unites industry leaders, groundbreaking researchers, and passionate enthusiasts to explore synergies and untapped potential within these fields. Join thousands of attendees as we unlock the secrets to a brighter future.
Learn more at https://wonderlandconference.com and save the dates for 2024.
Ibogaine is a non-classical psychedelic that breaks the cycle of addiction to opioids, cocaine and other abused drugs. In the 1960’s, American and European self-help groups provided public testimonials that a single dose of ibogaine alleviated drug craving, opioid withdrawal symptoms, and prevented relapse for weeks, months and sometimes years. The claimed therapeutic benefits of ibogaine which treat the underlying disease instead of targeting symptoms to prevent relapse support the current resurgence of ibogaine’s clinical development for inpatient use.
Featured Speakers
Deborah Mash, CEO & Founder, DemeRx
Deborah Mash is one of the world’s foremost experts on the hallucinogenic drug ibogaine. She is the CEO and Founder of DemeRx Inc., a clinical stage drug development company advancing ibogaine and noribogaine for the treatment of opioid use disorder. DemeRx has partnered with ATAI Life Sciences — a global biotech platform with a special focus on psychedelic medicine — to develop ibogaine for those suffering from opioid use disorder.
Wonderland is the place to discover the fascinating worlds of psychedelic medicine, mental health, and longevity. An immersive environment, our conference programming and experience floor unites industry leaders, groundbreaking researchers, and passionate enthusiasts to explore synergies and untapped potential within these fields. Join thousands of attendees as we unlock the secrets to a brighter future.
Learn more at https://wonderlandconference.com and save the dates for 2024.
){kind=link}
Thank you!! We need relief and as much push for FDA approval as possible!